References
- Pemán J, Cantón E, Espinel-Ingroff A. Antifungal drug resistance mechanisms. Expert Rev. Anti Infect. Ther.7(4), 453–460 (2009).
- Botter AA. Topical treatment of nail and skin infections with miconazole, a new broad-spectrum antimycotic. Mykosen14(4), 187–191 (1971).
- Brincker H. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Med. Scand.204(1–2), 123–128 (1978).
- Barasch A, Griffin AV. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol.3, 265–269 (2008).
- Fothergill AW. Miconazole: a historical perspective. Expert Rev. Anti Infect. Ther.4(2), 171–175 (2006).
- Francois IEJA, Cammune BPA, Borgers M, Ausma J, Dispersyn GD, Thevissen K. Azoles: mode of antifungal action and resistance development. Effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Anti Infect. Agents Med. Chem.5, 3–13 (2006).
- Kobayashi D, Kondo K, Uehara N et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother.46(10), 3113–3117 (2002).
- Trovato L, Rapisarda MF, Greco AM, Galata F, Oliveri S. In vitro susceptibility of nondermatophyte molds isolated from onycomycosis to antifungal drugs. J. Chemother.21(4), 403–407 (2009).
- Pietschmann S, Hoffmann K, Voget M, Pison U. Synergistic effects of miconazole and polymyxin B on microbial pathogens. Vet. Res. Commun.33, 489–505 (2009).
- Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses (2009) (Epub ahead of print).
- Carrilo-Munoz AJ, Tur C, Torres J. In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. J. Antimicrob. Chemother.37(4), 815–819 (1996).